NeuroMab™ Anti-Notch2/3 BBB Shuttle Antibody(NRZP-1022-ZP3240)

Figure 1. OMP-59R5 activity in OMP-PN8 pancreatic tumor cells as a single agent or in combination with chemotherapeutic agents.

Figure 2. Activity of OMP-59R5 as a single agent or in combination with chemotherapeutic agents in OMP-PN811 pancreatic tumor cells.

Figure 3. The correlation between NOTCH3 expression and pancreatic tumor growth inhibition and OMP-59R5 combined with gemcitabine. The inhibition degree of OMP-59R5 antibody combined with gemcitabine on pancreatic tumors was significantly correlated with the expression level of NOTCH3 in pancreatic tumor cells.

Figure 4. Distribution of NOTCH3 expression in pancreatic tumors responding (R) and non-responding (NR) to OMP-59R5 antibody combined with gemcitabine therapy. NOTCH3 expression distributions are shown as boxplots depicting the sample minimum, lower quartile, median, upper quartile, and sample maximum.

Figure 5. NOTCH3 expression in representative pancreatic cancer tissues as determined by immunohistochemistry (IHC) assay.

Graph shows pancreatic tumors with high NOTCH3 expression and pancreatic tumors with moderate NOTCH3 expression.

Figure 6. NOTCH3 expression in representative pancreatic cancer tissues as determined by immunohistochemistry (IHC) assay.

Graph shows pancreatic tumors with low NOTCH3 expression and pancreatic tumors without NOTCH3 expression.

Figure 7. NOTCH3 expression in representative pancreatic cancer tissues as determined by immunohistochemistry (IHC) assay.

Graphs show lung tumors with high NOTCH3 expression (OMPLU90), lung tumors with low NOTCH3 expression (OMP-LU40), and lung tumors without NOTCH3 expression (OMP-LU66).

Figure 8. Distribution of NOTCH3 expression in pancreatic tumors responding (R) and non-responsive (NR) to OMP-59R5 antibody plus gemcitabine therapy as measured by IHC assay. NOTCH3 expression distributions are shown as boxplots depicting the sample minimum, lower quartile, median, upper quartile, and sample maximum.